Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Courtney D DiNardo & Jorge E Cortes. (2015) New treatment for acute myelogenous leukemia. Expert Opinion on Pharmacotherapy 16:1, pages 95-106.
Read now
Read now
Articles from other publishers (25)
BRANDON J kale, Nathaniel R Wilson & Naveen Pemmaraju. 2024. Manual of Hematopoietic Cell Transplantation and Cellular Therapies. Manual of Hematopoietic Cell Transplantation and Cellular Therapies
205
216
.
Sandra Kannampuzha, Reshma Murali, Abilash Valsala Gopalakrishnan, Anirban Goutam Mukherjee, Uddesh Ramesh Wanjari, Arunraj Namachivayam, Alex George, Abhijit Dey & Balachandar Vellingiri. (2023) Novel biomolecules in targeted cancer therapy: a new approach towards precision medicine. Medical Oncology 40:11.
Crossref
Crossref
Xiaoxia Liang, Pan Wu, Qian Yang, Yunyu Xie, Changliang He, Lizi Yin, Zhongqiong Yin, Guizhou Yue, Yuanfeng Zou, Lixia Li, Xu Song, Cheng Lv, Wei Zhang & Bo Jing. (2021) An update of new small-molecule anticancer drugs approved from 2015 to 2020. European Journal of Medicinal Chemistry 220, pages 113473.
Crossref
Crossref
Xiaoxia Liang, Qian Yang, Pan Wu, Changliang He, Lizi Yin, Funeng Xu, Zhongqiong Yin, Guizhou Yue, Yuanfeng Zou, Lixia Li, Xu Song, Cheng Lv, Wei Zhang & Bo Jing. (2021) The synthesis review of the approved tyrosine kinase inhibitors for anticancer therapy in 2015–2020. Bioorganic Chemistry 113, pages 105011.
Crossref
Crossref
Yi Long, Mingfeng Yu, Aleksandra M. Ochnik, Jasmine D. Karanjia, Sunita KC. Basnet, Alemwork A. Kebede, Lianmeng Kou & Shudong Wang. (2021) Discovery of novel 4-azaaryl-N-phenylpyrimidin-2-amine derivatives as potent and selective FLT3 inhibitors for acute myeloid leukaemia with FLT3 mutations. European Journal of Medicinal Chemistry 213, pages 113215.
Crossref
Crossref
Yue Zhong, Run-Ze Qiu, Shan-Liang Sun, Chao Zhao, Tian-Yuan Fan, Min Chen, Nian-Guang Li & Zhi-Hao Shi. (2020) Small-Molecule Fms-like Tyrosine Kinase 3 Inhibitors: An Attractive and Efficient Method for the Treatment of Acute Myeloid Leukemia. Journal of Medicinal Chemistry 63:21, pages 12403-12428.
Crossref
Crossref
Rui‐Qi Wang, Chong‐Jian Chen, Yu Jing, Jia‐Yue Qin, Yan Li, Guo‐Feng Chen, Wei Zhou, Yong‐Hui Li, Juan Wang, Da‐Wei Li, Hong‐Mei Zhao, Bian‐Hong Wang, Li‐Li Wang, Hong Wang, Meng‐Zhen Wang, Xiao‐Ning Gao & Li Yu. (2020) Characteristics and prognostic significance of genetic mutations in acute myeloid leukemia based on a targeted next‐generation sequencing technique. Cancer Medicine 9:22, pages 8457-8467.
Crossref
Crossref
Khalil Saleh, Nadine Khalifeh-Saleh & Hampig Raphael Kourie. (2020) Acute myeloid leukemia transformed to a targetable disease. Future Oncology 16:14, pages 961-972.
Crossref
Crossref
Longzhen Cui, Yan Liu, Yifan Pang, Tingting Qian, Liang Quan, Zhiheng Cheng, Yifeng Dai, Xu Ye, Ying Pang, Jinlong Shi, Xiaoyan Ke, Depei Wu & Lin Fu. (2019) Emerging agents and regimens for treatment of relapsed and refractory acute myeloid leukemia. Cancer Gene Therapy 27:1-2, pages 1-14.
Crossref
Crossref
Daniel A. Pollyea. (2018) Which novel agents for acute myeloid leukemia are likely to change practice?. Best Practice & Research Clinical Haematology 31:4, pages 391-395.
Crossref
Crossref
Daniel A. Pollyea. (2018) New drugs for acute myeloid leukemia inspired by genomics and when to use them. Hematology 2018:1, pages 45-50.
Crossref
Crossref
Mark C. Weir, Sherry T. Shu, Ravi K. Patel, Sabine Hellwig, Li Chen, Li Tan, Nathanael S. Gray & Thomas E. Smithgall. (2018)
Selective Inhibition of the Myeloid Src-Family Kinase Fgr Potently Suppresses AML Cell Growth
in Vitro
and
in Vivo
. ACS Chemical Biology 13:6, pages 1551-1559.
Crossref
Crossref
Tomáš Gucký, Eva Řezníčková, Tereza Radošová Muchová, Radek Jorda, Zuzana Klejová, Veronika Malínková, Karel Berka, Václav Bazgier, Haresh Ajani, Martin Lepšík, Vladimír Divoký & Vladimír Kryštof. (2018)
Discovery of
N
2
-(4-Amino-cyclohexyl)-9-cyclopentyl-
N
6
-(4-morpholin-4-ylmethyl-phenyl)-
9H
-purine-2,6-diamine as a Potent FLT3 Kinase Inhibitor for Acute Myeloid Leukemia with FLT3 Mutations
. Journal of Medicinal Chemistry 61:9, pages 3855-3869.
Crossref
Crossref
Shanhao Tang, Hongjie Shen, Xinliang Mao, Haiping Dai, Xiaming Zhu, Shengli Xue, Zixuan Ding, Jing Lu, Depei Wu & Xiaowen Tang. (2017) FLT3-ITD with DNMT3A R882 double mutation is a poor prognostic factor in Chinese patients with acute myeloid leukemia after chemotherapy or allogeneic hematopoietic stem cell transplantation. International Journal of Hematology 106:4, pages 552-561.
Crossref
Crossref
Kate McArthur, Akshay A. D’Cruz, David Segal, Kurt Lackovic, Andrew F. Wilks, Joanne A. O’Donnell, Cameron J. Nowell, Motti Gerlic, David C.S. Huang, Christopher J. Burns & Ben A. Croker. (2017) Defining a therapeutic window for kinase inhibitors in leukemia to avoid neutropenia. Oncotarget 8:35, pages 57948-57963.
Crossref
Crossref
Sofie Martens, Manhyung Jeong, Wulf Tonnus, Friederike Feldmann, Sam Hofmans, Vera Goossens, Nozomi Takahashi, Jan Hinrich Bräsen, Eun-Woo Lee, Pieter Van der Veken, Jurgen Joossens, Koen Augustyns, Simone Fulda, Andreas Linkermann, Jaewhan Song & Peter Vandenabeele. (2017) Sorafenib tosylate inhibits directly necrosome complex formation and protects in mouse models of inflammation and tissue injury. Cell Death & Disease 8:6, pages e2904-e2904.
Crossref
Crossref
Gevorg Tamamyan, Tapan Kadia, Farhad Ravandi, Gautam Borthakur, Jorge Cortes, Elias Jabbour, Naval Daver, Maro Ohanian, Hagop Kantarjian & Marina Konopleva. (2017) Frontline treatment of acute myeloid leukemia in adults. Critical Reviews in Oncology/Hematology 110, pages 20-34.
Crossref
Crossref
Singkome Tima, Siriporn Okonogi, Chadarat Ampasavate, Chad Pickens, Cory Berkland & Songyot Anuchapreeda. (2016) Development and Characterization of FLT3-Specific Curcumin-Loaded Polymeric Micelles as a Drug Delivery System for Treating FLT3-Overexpressing Leukemic Cells. Journal of Pharmaceutical Sciences 105:12, pages 3645-3657.
Crossref
Crossref
Marlise R. Luskin, Phyllis A. Gimotty, Catherine Smith, Alison W. Loren, Maria E. Figueroa, Jenna Harrison, Zhuoxin Sun, Martin S. Tallman, Elisabeth M. Paietta, Mark R. Litzow, Ari M. Melnick, Ross L. Levine, Hugo F. Fernandez, Selina M. Luger, Martin Carroll, Stephen R. Master & Gerald B.W. Wertheim. (2016) A clinical measure of DNA methylation predicts outcome in de novo acute myeloid leukemia. JCI Insight 1:9.
Crossref
Crossref
Naveen Pemmaraju, Hagop Kantarjian, Farhad Ravandi, Graciela M. Nogueras-Gonzalez, Xuelin Huang, Susan O'Brien, William Wierda, Guillermo Garcia-Manero, Deborah Thomas, Sherry Pierce, Srdan Verstovsek, Gautam Borthakur & Jorge Cortes. (2016) Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML). Clinical Lymphoma Myeloma and Leukemia 16:4, pages 213-222.e2.
Crossref
Crossref
Harinder Gill, Anskar Leung & Yok-Lam Kwong. (2016) Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy. International Journal of Molecular Sciences 17:4, pages 440.
Crossref
Crossref
Harinder Gill, Anskar YH Leung & Yok-Lam Kwong. (2016) Molecularly targeted therapy in acute myeloid leukemia. Future Oncology 12:6, pages 827-838.
Crossref
Crossref
Elisa Zuffa, Eugenia Franchini, Cristina Papayannidis, Carmen Baldazzi, Giorgia Simonetti, Nicoletta Testoni, Maria Chiara Abbenante, Stefania Paolini, Chiara Sartor, Sarah Parisi, Giovanni Marconi, Federica Cattina, Maria Teresa Bochicchio, Claudia Venturi, Emanuela Ottaviani, Michele Cavo & Giovanni Martinelli. (2015) Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients. Oncotarget 6:31, pages 31284-31294.
Crossref
Crossref
Rimma Berenstein. (2015) Class III Receptor Tyrosine Kinases in Acute Leukemia – Biological Functions and Modern Laboratory Analysis. Biomarker Insights 10s3, pages BMI.S22433.
Crossref
Crossref
Naveen Pemmaraju, Hagop Kantarjian, Guillermo Garcia-Manero, Sherry Pierce, Marylou Cardenas-Turanzas, Jorge Cortes & Farhad Ravandi. (2015) Improving outcomes for patients with acute myeloid leukemia in first relapse: A single center experience. American Journal of Hematology 90:1, pages 27-30.
Crossref
Crossref